MX345184B - Gold nanoparticles radiolabelled with 99mtc and conjugated to peptides c [rgdfk(c)] as a novel radiopharmaceutical for the detection in vivo of angiogenesis.
- Google Patents
Gold nanoparticles radiolabelled with 99mtc and conjugated to peptides c [rgdfk(c)] as a novel radiopharmaceutical for the detection in vivo of angiogenesis.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nac De Investig NuclearesfiledCriticalInst Nac De Investig Nucleares
Priority to MX2012003633ApriorityCriticalpatent/MX345184B/en
Publication of MX2012003633ApublicationCriticalpatent/MX2012003633A/en
Publication of MX345184BpublicationCriticalpatent/MX345184B/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
The present invention refers to a novel heterofunctional, multimeric and multivalent radiopharmaceutical of gold nanoparticles, which are multilabelled with Technetium-99m (99mTc) and conjugated to hundreds of cyclo peptides [Arg-Gly-Asp-D-Phe (Cys)] (c(RGDfk)C) as an agent for the detection in vivo of angiogensesis in the early diagnosis of aggressive tumours of quick growth and metastasis as breast cancer and glioblastoma, by techniques of molecular image in nuclear medicine. The purpose of the present invention is to provide a novel specific radiopharmaceutical (molecular target radiopharmaceutical) for the detection in vivo of angiogenesis (over-expression of integrin a(v) ß(3), which is totally different from those currently available on the market.
MX2012003633A2012-03-272012-03-27Gold nanoparticles radiolabelled with 99mtc and conjugated to peptides c [rgdfk(c)] as a novel radiopharmaceutical for the detection in vivo of angiogenesis.
MX345184B
(en)
Gold nanoparticles radiolabelled with 99mtc and conjugated to peptides c [rgdfk(c)] as a novel radiopharmaceutical for the detection in vivo of angiogenesis.
Gold nanoparticles radiolabelled with 99mtc and conjugated to peptides c [rgdfk(c)] as a novel radiopharmaceutical for the detection in vivo of angiogenesis.
Gold nanoparticles radiolabelled with 99mtc and conjugated to peptides c [rgdfk(c)] as a novel radiopharmaceutical for the detection in vivo of angiogenesis.
Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer.
Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
Gold nanoparticles radiolabelled with 99mtc and conjugated to peptides c [rgdfk(c)] as a novel radiopharmaceutical for the detection in vivo of angiogenesis.
GOLD NANOPARTICLES RADIOLABELLED WITH 177LU AND CONJUGATED TO PEPTIDES C (RGDFK) C AS A NOVEL RADIOPHARMACEUTICAL FOR THE THERAPY OF TUMORS OVER-EXPRESSING INTEGRINS A (V) ß (3).
Virus-like vector particle, method of its production, application of the virus-like vector particle and the farmaceutical composition containing the virus-like vector particle,